CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Operating activities
Net loss	$ (37,733)	$ (34,137)
Less: Net income from discontinued operations		28,915
Net loss from continuing operations	(37,733)	(63,052)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,177	1,949
Amortization and accretion income, net	(1,092)	(31)
Future royalty payment contingency interest accretion	1,118
Share-based compensation	13,285	24,254
Gain on sale of Velusetrag		(2,721)
(Gain) loss on disposal of property and equipment	1,352	(96)
Gain from lease modification		(47)
Amortization of right-of-use assets	1,817	1,314
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	989	1,577
Prepaid clinical and development services	533	7,934
Other prepaid and current assets	(95)	2,619
Right-of-use lease assets	(144)	(2,689)
Other assets	1,751	(145)
Accounts payable	83	(26)
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(6,534)	(11,135)
Deferred revenue	(11)	(180)
Operating lease liabilities	(479)	82
Other long-term liabilities	326	(17)
Net cash used in operating activities - continuing operations	(23,657)	(40,410)
Net cash used in operating activities - discontinued operations		(389)
Net cash used in operating activities	(23,657)	(40,799)
Investing activities
Purchases of property and equipment	(1,790)	(363)
Purchases of marketable securities	(134,534)	(53,763)
Maturities of marketable securities	31,435	91,699
Sale of short-term investments and marketable securities	71,377
Proceeds from the sale of property and equipment	1,513	1,866
Net cash (used in) provided by investing activities - continuing operations	(31,999)	39,439
Net cash provided by (used in) investing activities - discontinued operations
Net cash (used in) provided by investing activities	(31,999)	39,439
Financing activities
Ordinary share repurchases	(135,896)
Proceeds from ESPP purchases	446	487
Repurchase of shares to satisfy tax withholding	(1,470)	(1,795)
Net cash used in financing activities - continuing operations	(136,920)	(1,308)
Net cash provided by (used in) financing activities - discontinued operations
Net cash used in financing activities	(136,920)	(1,308)
Net decrease increase in cash, cash equivalents, and restricted cash	(192,576)	(2,668)
Cash, cash equivalents, and restricted cash at beginning of period	299,008	90,796
Cash, cash equivalents, and restricted cash at end of period	106,432	88,128
Supplemental disclosure of cash flow information
Cash paid for interest		15,127
Cash paid for income taxes, net	14	$ 25
Supplemental disclosure of non-cash investing and financing activities
Recognition of tenant improvement allowance assigned to sublease	$ 6,490